Join Us at Drafts & Discoveries: South San Francisco
Join EditCo, Promega & Ncardia on Oct. 8 for a scientific exchange on protein degradation and cell models.
Metrics of Success
Skip the editing and get to your research with EditCo’s intelligent CRISPR design and custom-engineered cells.
- 0+
- Edits Performed
- 0%
- guaranteed editing efficiency
- 0+
- Cell Lines
- 0+
- Publications
Explore CRISPR kits and engineered cell services.
Edited Immortalized Cells
Knockout Immortalized Cell Lines
CRISPR knockout cells streamline gene editing, providing ready-to-use cell lines and eliminating months of optimization.See Knockout CellsKnock-in Immortalized Cell Lines
Receive precision edits for disease modeling and protein studies, bypassing the complexity of DIY CRISPR.See Knock-in CellsEdited iPS Cells
Knockout iPS Cell Lines
EditCo’s CRISPR Knockout iPS Cells ensure industry-leading editing efficiency in iPS cells, without compromising cell quality. Get reliable gene knockout for critical gene function and disease linkage studies with the assurance of cell integrity.See Knockout iPS Cell LinesKnock-in iPS Cell Lines
EditCo’s advanced CRISPR knock-in edits in iPS cells unlock breakthrough potential in neuroscience and regenerative medicine. Our efficient automated process for high-quality reproducible iPS cell edits paves the way for your groundbreaking research and therapeutic development.See Knock-in iPS Cell LinesEdited Primary Cells
Knockout CD8+ and CD4+ T cells
Advance your immunology research with edited-to-order primary CD8+ and CD4+ T cells. Unparalleled editing accuracy and efficiency enable you to bypass the time and resources spent on optimization. EditCo’s consistent and functional T cells ensure post-editing experimental reliability and robust downstream results.See Knockout CD4+ & CD8+ T cellsKnockout Fibroblast Cells
Focus on the main experiment with made-to-order KO Fibroblast Cells. Whether you are studying autoimmunity, tumor micro-environments in cancer, wound healing, or other fibrotic diseases, EditCo has the solution to generate disease relevant models. EditCo’s XDel Technology enables high on-target editing efficiency in your disease models or target screens with Fibroblasts.See Knockout Fibroblast CellsCRISPR Kits & Reagents
Gene Knockout Kits
Knockout any human or mouse protein-coding gene with our unique multi-guide RNA strategy. Three spatially coordinated modified SpCas9 sgRNAs induce fragment deletions, obtaining knockout rates greater than 80 percent, and it ships in as few as 5 days.See Gene Knockout KitsArrayed CRISPR sgRNA Libraries
Achieve reliably high knockout efficiencies across your entire CRISPR screen for any human or mouse protein-coding gene. Identifying and validating your targets has never been faster and more reliable, with unparalleled quick delivery starting at 7 days and consistently high editing efficiency.See Arrayed CRISPR sgRNA LibrariesNucleases & Controls
EditCo’s highly efficient CRISPR kits simplify your science. Complete your CRISPR experiment with Cas9 Nucleases, gRNA Control Kits, CRISPR Transfection Reagents, and more.See Nucleases & ControlsYour Trusted Partner for Rapid, Precise, Reproducible and High Value Genome Engineering
High Efficiency. Reproducible Edits
- >98% avg. editing efficiency in KO
- >50% avg. editing efficiency in KIs (HiBiT, SNV)
- >90% cell viability across passages
- >94% project success rate
Fast Results. On-Time
- XDel KO Pools = 2–4 weeks
- XDel KO Clones = 8–10 weeks
- KI Pools = 6–9 weeks
- KI Clones = 10–14 weeks
Scale Fast. Across Cell Lines
- Automated platform scalable to hundreds of edits in parallel
- Access to > 1,400 cell lines:
- Immortalized, iPSC and primary T-cells & Fibroblast
Real Value.
- Collaborative, transparent, dependable
- Editing efficiency guarantee
- Expert support & communication
- Easy & Simple
- Positive economic impact
At EditCo, our journey began within the pioneering gene-editing landscape of Synthego. Building on this expertise, we expanded into our own company in early 2024, offering high-quality gene editing services with a focus on precision cell engineering. With our experience as CRISPR leaders, our innovative editing platform, and the highest-quality gene editing products, we're here to propel our customers' scientific breakthroughs.
Trusted by researchers worldwide
As researchers studying SURF2's role in cancer resistance to chemotherapy, we investigated its depletion in U2OS and HepG2 cell lines. While siRNA yielded initial insights, we sought a more robust approach and partnered with EditCo to generate CRISPR knockout pools. They provided 100% homozygous deletions quickly, allowing us to validate results, isolate clones, and assess SURF2 knockout effects. This work led to our publication in Nature Communications (Tagnères et al.) and continues to drive our research. EditCo’s expertise and efficiency were instrumental, and we look forward to future collaborations.
Simon LebaronPhD-HDR, CRCN INSERM. Université de Toulouse (CBI, MCD Unit), France.EditCo has proven to be an invaluable partner in advancing our—and our client's—research. We highly recommend their gene editing services to any organization seeking a reliable, efficient, and skilled collaborator in the field of gene editing.
Alice RoworthCOO, ArctorisATCC and EditCo’s strategic partnership brings together the gold standard in authenticated cell lines with EditCo’s leading CRISPR tools and gene editing services. This powerful alliance allows researchers to harness the highest-quality edited cells, accelerating their research with unparalleled speed, precision, reproducibility, and quality.
Viqar AslamSenior Director, Strategic Partnerships, ATCCWe chose EditCo’s Arrayed CRISPR Library for our screening project after testing different reagents and finding that the multi-guide RNA design results in superior editing and knockout efficiency. This superior efficiency improves the sensitivity of our screen by enhancing our ability to detect phenotypes—in particular, weak phenotypes—resulting from knockouts.
Marco Jost, Ph.D.Assistant Professor of Microbiology
AI, CRISPR, and Automation in Oncology Drug Discovery
Learn how the team at Evariste has been using AI to accelerate drug discovery, along with the help of two powerful automated platforms: CRISPR editing through EditCo’s XDel Cell Pools and assay development through Arctoris' Ulysses.- 10,000
- Gene Pairs IDed in Silico
- 72
- Cell Lines Generated
- 10+
- Novel Drug Targets Validated
Explore recent developments in genome engineering and XDel multi-guide CRISPR kits.
Brochure
EditCo Capabilities BrochureDiscover how EditCo is redefining genome engineering with high-efficiency CRISPR knockouts, knock-ins, and functional tags, built for scalable, reproducible, biologically relevant results.Read More
Application Note
XDel Technology Enables Sustained Protein Depletion and Simplified Genotyping Compared with Conventional CRISPR Guide DesignsLearn how XDel CRISPR knockout technology achieves sustained protein depletion, larger fragment deletions & simplified genotyping compared with conventional guide designs.Read More
Application Note
CRISPR-Engineered Cells Enable Variant Disease ModelingUnderstand how all researchers can leverage CRISPR-engineered cells to model multiple genetic variants and clones at scale.Read More
E-Book
Cell Engineering 101 eBookDiscover methods and insights into skillfully generating knockout or knock-in CRISPR edits in a wide-range of cell lines.Read More
Application Note
XDel CRISPR Technology Improves CRISPR Efficiency by Generating Fragment DeletionsLearn how XDel CRISPR Technology improve CRISPR knockout efficiency with single exon fragment deletions.Read More